WEX Pharmaceuticals Inc. (“WEX” or the “Company”) is a private biopharmaceutical company based in Vancouver, Canada, developing a new class of non-opioid analgesics. WEX’s proprietary platform and the lead product is Halneuron®. The active pharmaceutical ingredient in Halneuron is Tetrodotoxin (“TTX”) which is a proven sodium channel blocker.
Halneuron is in Phase III clinical development for the treatment of cancer-related pain and will commence Phase III clinical development for chemotherapy-induced neuropathic pain. WEX has conducted over 15 clinical trials with TTX and has treated more than 500 people to date.
WEX is a wholly-owned subsidiary of CK Life Sciences Int’l. Inc. (“CKLS”), listed on the Hong Kong Stock Exchange (stock code: 0775). CKLS is engaged in the business of research and development, manufacturing, commercialization, marketing and selling of environmental and human health products. CKLS is a member of the CK Hutchison Group. For additional information, please visit www.ck-lifesciences.com.
Led With Technical Expertise
WEX is led by executives with a strong technical background in pharmaceuticals and life sciences.
Dolor Set Imet
WEX is developing a new class of non-opioid analgesics. The Company’s proprietary platform is Halneuron® (TTX), a highly selective sodium channel blocker. WEX’s lead product Halneuron® based on TTX is in Phase III clinical development for the treatment of cancer related pain and starting Phase III for chemotherapy induced neuropathic pain.
WEX is a subsidiary of CK Life Sciences Int’l., (Holdings) Inc. (“CKLS”), listed on The Stock Exchange of Hong Kong Limited (stock code: 0775). CKLS is engaged in the business of research and development, manufacturing, commercialization, marketing and selling of environmental and human health products, and water businesses and investment in various financial and investment products. CKLS is a member of the CK Hutchison Group.
Led With Technical Expertise
Our Leadership Team
Chief Operating Officer
Mr. Korz has over 35 years of multi-disciplinary life sciences experience gained in public healthcare and holding senior management positions with several emerging and established life sciences companies. Mr. Korz joined WEX in November 2010 and has a broad drug development background with significant experience in business development, finance, clinical development, regulatory affairs and project outsourcing.
Before WEX, Mr. Korz was Vice President, Drug Development and then President and CEO of Chemokine Therapeutics Corp. Mr. Korz was Clinical Development Manager with Angiotech Pharmaceuticals Inc. overseeing systemic therapy programs for rheumatoid arthritis, psoriasis, including one of Canada’s largest multiple sclerosis clinical trials. Much of his career was involved in cancer research during his service with AltaRex Corp and Biomira Research. where he was responsible for the development of therapeutic products, clinical trials, and regulatory filings.
Mr. Korz is a graduate from Southern Alberta Institute of Technology and the University of Saskatchewan and has a Masters of Business Administration from Athabasca University.
Chief Financial Officer
Mr. Buckland has extensive experience in the development of financial operations in both large multinational and early-to-mid sized corporations. Mr. Buckland has a diverse background in international business and over fifteen years as the most senior financial officer U.S. public and pre-IPO life sciences companies.
In addition to WEX, Mr. Buckland is the Chief Financial Officer of Polynoma LLC which is also a subsidiary of CK Life Sciences Int’l (Holdings) Inc.
Mr. Buckland previously served as Chief Financial Officer of PURE Bioscience, Inc., a company that grew from the OTC Bulletin Board to the NASDAQ Stock Exchange. Prior to PURE Bioscience, Mr. Buckland served as Vice President of Finance at Cardionet, Inc., as Chief Financial Officer of Advanced Tissue Sciences, Inc., a NASDAQ-listed public biotechnology company, and held senior accounting and finance management positions at Bristol-Myers Squibb and United Parcel Service.
Mr. Buckland has completed several private placements and registered direct common stock placements and registered direct common stock offerings in the United States, and obtained SEC effectiveness on multiple registration statements. Mr. Buckland earned an MBA from the University of California, Irvine and a BA (with Honors) from the University of the West of England.
Dr. Meng Zhou
Vice President, Manufacturing
Meng joined WEX as Vice President of Manufacturing in July 2018. He brought 19 years of pharmaceutical industry experience in drug delivery, formulation development, analytical chemistry, natural product research, clinical trial supply manufacturing, process scale-up and commercialization. At WEX, Meng is responsible for CMC activities to advance the technology to late phase clinical studies and secure a complex global supply chain. Before WEX, Meng worked in various positions in Big Pharma, Specialty Pharma, and CDMOs. From 2016 to 2018, Meng served as Sr. Director of R&D in SteriMax Inc. specialized in injectable product development. From 2011 to 2016, Meng directed the PDS group in Contract Pharmaceutical Limited (CPL) to support numerous NDA, ANDA and 505(b)2 projects from a global client base. Prior to CPL, Meng held research scientist positions at Patheon Inc., Endo Pharmaceuticals, and ALZA Corporation, a J&J Company. Meng earned his Ph.D. in Pharmaceutical Science from the University of Georgia in 2001, MS in Technology Management from Steven Institute of Technology in 2007, and BS in Medicinal Chemistry from Beijing Medical University in 1997. Be
Abner Yong, CPA, CA
Vice President, Finance
Abner joined WEX Pharmaceuticals Inc. in March 2018 following over 14 years of accounting, corporate finance, treasury and transactions experience gained in an investment-grade multinational company and a Big 4 accounting firm. Prior to WEX, Abner held finance positions at Methanex Corporation, a Vancouver based NASDAQ/TSX listed multinational chemicals manufacturer and distributor, in corporate treasury and corporate accounting where he was responsible for financial operations, global budgeting, debt and credit financings, global treasury, compliance and financial talent development. Prior to Methanex, Abner was with Ernst & Young in Transactions Advisory Services where he was engaged in numerous debt and credit financings, corporate restructurings and corporate transactions across Canada.